公开(公告)号：US20210199659A1

公开(公告)日：2021-07-01

申请号：US17186163

申请日：2021-02-26

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Vinzent Rolny ,  Sandra Rutz ,  David Morgenstern ,  Boris Pinchuk ,  Christina Zimmermann ,  Martin Klammer ,  Franziska Sonner

IPC: G01N33/573 ,  G01N33/574

Abstract: The present disclosure relates to the finding that thymidine kinase 1 (TK-1) represents a valuable biomarker in a method for determining a Prognostic Index (PI) for risk stratification of a patient with aggressive B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL), to the use of TK-1 in such PI and to a PI comprising the marker TK-1.

公开(公告)号：US20230305010A1

公开(公告)日：2023-09-28

申请号：US18309985

申请日：2023-05-01

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Farshid Dayyani ,  Anika Mang ,  David Morgenstern ,  Vinzent Rolny ,  Magdalena Swiatek-De Lange

IPC: G01N33/574

CPC classification number: G01N33/57438 ,  G01N2333/8146 ,  G01N2333/96494 ,  G01N2470/04 ,  G01N2800/50 ,  G01N2800/08

Abstract: The present invention relates to an in vitro method for assessing cholangiocarcinoma in a patient sample, comprising the steps of: a) determining the level of tissue inhibitor of metalloproteinase-1 (TIMP1) in the patient sample, wherein the patient sample is selected from a group consisting of serum, plasma and whole blood sample from an individual, b) comparing the level of TIMP1 determined in step (a) with a reference level of TIMP1, and c) assessing cholangiocarcinoma in the patient sample by comparing the level determined in step (a) to the reference level of TIMP1, wherein an increased level of TIMP1 compared to the reference level of TIMP1 is indicative for cholangiocarcinoma in the patient sample. Further, the present invention relates to an in vitro method for assessing cholangiocarcinoma comprising TIMP1 and MMP2, the use of TIMP1 and optionally MMP2 in the in vitro assessment of CCA, and a kit for performing the said methods.

公开(公告)号：US20180364230A1

公开(公告)日：2018-12-20

申请号：US16111347

申请日：2018-08-24

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Herbert Andres ,  Johann Karl ,  Ursula Kunert ,  David Morgenstern ,  Nina Meissler ,  Marion Niessner ,  Magdalena Swiatek-de Lange

IPC: G01N33/564 ,  G01N33/574 ,  C07K16/46

Abstract: The disclosure relates to an in vitro method for detecting an antibody to p53 (anti-p53 antibody) in a sample, the method comprising: incubating a sample to be analyzed with a p53 capture antigen and a p53 detection antigen, whereby a complex comprising the p53 capture antigen, the anti-p53 antibody and the p53 detection antigen is formed, separating the complex formed from unbound detection antigen and measuring the complex obtained via the detection antigen comprised therein, thereby detecting the anti-p53 antibody comprised in the sample.

公开(公告)号：US20240272154A1

公开(公告)日：2024-08-15

申请号：US18616550

申请日：2024-03-26

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Herbert Andres ,  Johann Karl ,  Ursula Kunert ,  David Morgenstern ,  Nina Meissler ,  Marion Niessner ,  Magdalena Swiatek-de Lange

IPC: G01N33/564 ,  C07K16/46 ,  G01N33/574

CPC classification number: G01N33/564 ,  C07K16/46 ,  G01N33/574 ,  G01N33/5748 ,  G01N33/57496

Abstract: An in vitro method is disclosed for detecting an antibody to p53 (anti-p53 antibody) in a sample, the method comprising: incubating a sample to be analyzed with a p53 capture antigen and a p53 detection antigen, whereby a complex comprising the p53 capture antigen, the anti-p53 antibody and the p53 detection antigen is formed, separating the complex formed from unbound detection antigen and measuring the complex obtained via the detection antigen comprised therein, thereby detecting the anti-p53 antibody comprised in the sample.

公开(公告)号：US11971407B2

公开(公告)日：2024-04-30

申请号：US17730403

申请日：2022-04-27

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Herbert Andres ,  Johann Karl ,  Ursula Kunert ,  David Morgenstern ,  Nina Meissler ,  Marion Niessner ,  Magdalena Swiatek-de Lange

IPC: G01N33/53 ,  C07K16/46 ,  G01N33/564 ,  G01N33/574

CPC classification number: G01N33/564 ,  C07K16/46 ,  G01N33/574 ,  G01N33/5748 ,  G01N33/57496

Abstract: An in vitro method is disclosed for detecting an antibody to p53 (anti-p53 antibody) in a sample, the method comprising: incubating a sample to be analyzed with a p53 capture antigen and a p53 detection antigen, whereby a complex comprising the p53 capture antigen, the anti-p53 antibody and the p53 detection antigen is formed, separating the complex formed from unbound detection antigen and measuring the complex obtained via the detection antigen comprised therein, thereby detecting the anti-p53 antibody comprised in the sample.

公开(公告)号：US20220252592A1

公开(公告)日：2022-08-11

申请号：US17730403

申请日：2022-04-27

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Herbert Andres ,  Johann Karl ,  Ursula Kunert ,  David Morgenstern ,  Nina Meissler ,  Marion Niessner ,  Magdalena Swiatek-de Lange

IPC: G01N33/564 ,  G01N33/574 ,  C07K16/46

Abstract: The disclosure relates to an in vitro method for detecting an antibody to p53 (anti-p53 antibody) in a sample, the method comprising: incubating a sample to be analyzed with a p53 capture antigen and a p53 detection antigen, whereby a complex comprising the p53 capture antigen, the anti-p53 antibody and the p53 detection antigen is formed, separating the complex formed from unbound detection antigen and measuring the complex obtained via the detection antigen comprised therein, thereby detecting the anti-p53 antibody comprised in the sample.